Xinhuanet, Nanjing, May 23 (Reporter: Zhu Cheng) - On May 22, local time, the American Society of Clinical Oncology (ASCO) annual meeting announced the abstracts for selected studies. Among them, data from the Phase III clinical trial of the "Defu Combination" (Benmelstobart + Anlotinib capsules) from leading Hong Kong-listed pharmaceutical company Sino Biopharm for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC) was announced. It can significantly improve progression-free survival (PFS), reducing the risk of disease progression/death by 36%, and has a manageable safety profile, potentially bringing a new clinical treatment option to patients with squamous non-small cell lung cancer worldwide.

The study showed that among 565 patients with locally advanced or metastatic sq-NSCLC who had not previously received systemic treatment, the regimen of Benmelstobart combined with chemotherapy followed by sequential combination with Anlotinib achieved a median progression-free survival (PFS) of 10.12 months as of March 1, 2024.

Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences, the report's author and principal investigator of this clinical trial, stated that the regimen of Benmelstobart combined with chemotherapy followed by sequential combination with Anlotinib has broken through the bottleneck of traditional standard treatments and may change the existing treatment paradigm, providing an innovative first-line treatment model for patients with advanced squamous non-small cell lung cancer who have limited clinical treatment options.

Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm, stated that in the future, Sino Biopharm will leverage its own innovation and commercialization capabilities to accelerate the market entry of these innovative products, benefiting more patients and contributing to the further high-quality development of China's pharmaceutical innovation. (End)

Editor in Charge: Yu Lei